| tradename = Desoxyn
| Drugs.com = {{Drugs.com|monograph|methamphetamine-hydrochloride}}
| pregnancy_AU =
| pregnancy_US = C
| dependency_liability = [[Pheesical dependence|''Pheesical'']]: none<br />[[Psychological dependence|''Psychological'']]: heich
| addiction_liability = Heich
| legal_AU = S8
| legal_CA = Schedule I
| legal_NZ = Class A
| legal_UK = Class A
| legal_US = Schedule II
| legal_UN = Psychotropic Schedule II
| legal_DE = Anlage II
| licence_US = Methamphetamine
| routes_of_administration= Medical: [[Oral route|oral (ingestion)]], [[intravenous admeenistration|intravenous]]<ref name="RxMethIV">{{Cite book|title = Amphetamine legislation 1971: Hearings, Ninety-second Congress, first session, pursuant to S. Res. 32, section 12, investigation of juvenile delinquency in the United States|url = https://bulk.resource.org/gao.gov/91-513/000050D8.pdf|publisher = U.S. Govt. Print. Off.|date = 1 January 1972|last = United States Congress Senate Committee on the Judiciary Subcommittee to Investigate Juvenile Delinquincy|quote = We made a decision in January of 1969 to cease the manufacture of injectable methamphetamines.|page = 161|access-date = 1 January 2016|archive-date = 2010-05-06|archive-url = https://web.archive.org/web/20100506193205/http://bulk.resource.org/gao.gov/91-513/000050D8.pdf|url-status = dead}}</ref><br />Recreational: [[Oral route|oral]], [[intravenous admeenistration|intravenous]], [[intramuscular admeenistration|intramuscular]], [[subcutaneous admeenistration|subcutaneous]], [[smeukin|smeuk inhalation]], [[Insufflation (medicine)|insufflation]], [[Suppository|rectal]], [[intravaginal admeenistration|vaginal]]
<!--Pharmacokinetic data-->
| bioavailability= Oral: 70%<ref name="Bioavailability">{{cite journal | vauthors = Rau T, Ziemniak J, Poulsen D | title = The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury | journal = Prog. Neuropsychopharmacol. Biol. Psychiatry | volume = 64| issue = | pages = 231–6| year = 2015 | pmid = 25724762 | doi = 10.1016/j.pnpbp.2015.02.013 | quote = In humans, the oral bioavailability of methamphetamine is approximately 70% but increases to 100% following intravenous (IV) delivery (Ares-Santos et al., 2013).}}</ref><br/>IV: 100%<ref name="Bioavailability" />
| protein_bound = Varies widely<ref name="Pubchem1">{{cite encyclopedia | title=Methamphetamine | section-url=https://pubchem.ncbi.nlm.nih.gov/compound/1206#section=Toxicity | work=PubChem Compound | publisher = National Center for Biotechnology Information | accessdate=31 December 2013 | section=Toxicity}}</ref>
| metabolism = [[CYP2D6]]<ref name="FDA Pharmacokinetics">{{cite web | title = Adderall XR Prescribing Information | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf | pages = 12–13 | work = United States Food and Drug Administration |date=December 2013 | accessdate = 30 December 2013 }}</ref> and [[Flavin-containing monooxygenase 3|FMO3]]<ref name="FMO">{{cite journal |vauthors=Krueger SK, Williams DE | title = Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism | journal = Pharmacol. Ther. | volume = 106 | issue = 3 | pages = 357–387 |date=June 2005 | pmid = 15922018 | pmc = 1828602 | doi = 10.1016/j.pharmthera.2005.01.001 }}</ref>
| onset = Rapid<ref name=Ri2010/>